Skip To Main Content

Indication1

DUPIXENT is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.

SmPC

TARGET
Type 2 inflammation1-3
TREAT
full spectrum of symptoms1,12,13
CONTROL
with less surgery or fewer steroids1,13
Find out how > See the data > Learn more >

NP & Type 2 inflammation

Unmet need–Cycle of Recurrence

Type2Inflammation_CycleRecurrence

CRS with nasal polyps is not just an obstructive disease
CRS WITH NASAL POLYPS IS A CHRONIC TYPE 2 INFLAMMATORY DISEASE4-9

~9 out of 10 patients with CRS with nasal polyps have Type 2 inflammation, an underlying driver of complications including polyp formation4-9

icon

BREAK THE CYCLE WITH A BIOLOGIC THAT TARGETS TYPE 2 INFLAMMATION4-9

MOA graphic

DUPIXENT CENTRALLY TARGETS UNDERLYING TYPE 2 INFLAMMATION IN CRS WITH NASAL POLYPS1-3

MOA graphic

Efficacy and Burden data

Smell

PATIENTS REGAINED SMELL AS EARLY AS DAY 312,a

DUPIXENT improved smell loss (LoS) as early as Day 3, with a significantly greater proportion of patients with sense of smell (UPSIT score >18) vs placebo at Week 24 and sustained through Week 52 in patients receiving INCS1,12-14

Change in UPSIT score through Week 52 in SINUS-52 (secondary endpoint)13

Change in UPSIT score

icon

2 OUT OF 3 PATIENTS WERE ABLE TO SMELL AGAIN AT WEEK 521,13,b

SMELL LOSS IS ONE OF THE MOST IMPORTANT SYMPTOMS FOR PATIENTS15-18

~9 out of 10 patients who have CRS with nasal polyps experience loss of smell, which is correlated with increased disease severity and may be the first sign in the cycle of disease recurrence15-18

Smell loss is strongly associated with type 2 inflammation15-18

smell-loss

Smell loss

INHIBITING DRIVERS OF TYPE 2 INFLAMMATION MAY PLAY A ROLE IN IMPROVING SENSE OF SMELL15-18

Nasal congestion

RAPID IMPROVEMENT IN NASAL CONGESTION AT DAY 2 SUSTAINED OVER 52 WEEKS1,12,13

DUPIXENT improved NC score vs placebo as early as Day 2, with significant results at Week 24 and sustained through Week 52 in patients receiving INCS1,12,13

Change in NC score through Week 52 in SINUS-52 (secondary endpoint)13

Change in NC score

UNDERLYING TYPE 2 INFLAMMATION CAN DRIVE CONGESTION AND REDUCE QUALITY OF LIFE19

Nasal congestion drives many physical, social, and psychological HRQoL burdens related to CRS with nasal polyps19

Impacts of nasal congestion on HRQoL19

  • Depression
  • Self-consciousness
  • Loss of confidence
  • Inability to speak up clearly
  • Poor or disrupted sleep
  • Fatigue
  • Inability to concentrate
icon

MANY PATIENTS REPORTED FRUSTRATION WITH THE MANAGEMENT OF THEIR SYMPTOMS19

 

Surgery Reduction

LESS SURGERY FOR A MAJORITY OF PATIENTS1,13

DUPIXENT significantly reduced the need for sinus surgery vs placebo in over 52 weeks in patients receiving INCS1,13

icon

83% reduction in the need for initial or repeat sinus surgery1,13
From a prespecified pooled analysis (dupilumab 300 mg Q2W [Arm A] and 300 mg Q2W–Q4W [Arm B] pooled; First 24 weeks only for Arm B).2
†100 mg MFNS in each nostril twice daily.2
‡Saline nasal lavage, systemic antibiotics, short-course SCS, or sinonasal surgery were permitted as needed during the treatment and follow-up periods.13 Pooled placebo n=286, Pooled dupilumab n=438.

SURGERY MAY STILL LEAVE PATIENTS IN A CYCLE OF RECURRENCE20-22

Despite addressing polyp obstruction, surgery does not address the underlying Type 2 inflammation, which is associated with the disease burden of CRS with nasal polyps, including new polyp formation20-22

Burdens and limitations of surgery20-22

With each sinus surgery:

Risk of revision surgeries increases and duration between surgery decreases20

Sinus surgery does not address smell loss21

35% polyp recurrence rate within 6 months, increasing over time22

icon

EPOS GUIDELINES CONSIDER A REDUCED NEED FOR SURGERY AS A CRITERION OF BIOLOGIC RESPONSE22

Steroid Reduction

DUPIXENT TARGETS TYPE 2 INFLAMMATION TO REDUCE THE NEED FOR SYSTEMIC STEROIDS1,13

DUPIXENT significantly reduced the need for systemic steroids vs placebo over 52 weeks in patients receiving INCS1,13

icon

74% reduction in the need for systemic corticosteroid use1,13
From a prespecified pooled analysis (dupilumab 300 mg Q2W [Arm A] and 300 mg Q2W–Q4W [Arm B] pooled; first 24 weeks only for Arm B).2
†100 mg MFNS in each nostril twice daily.2
‡Saline nasal lavage, systemic antibiotics, short-course SCS, or sinonasal surgery were permitted as needed during the treatment and follow-up periods.13
Pooled placebo n=286, Pooled dupilumab n=438.

icon

DUPIXENT REDUCES OR ELIMINATES STEROID BURDEN REGARDLESS OF PRIOR SURGERY1

CUMULATIVE STEROID USE ADDS TO THE BURDENSOME CYCLE PATIENTS FACE22-24

SCS treatment broadly targets inflammation, and even short-term use carries a risk of serious short- and long-term side effects22-24

Limitations of SCS use22-24

The EPOS 2020 criteria advise not to prescribe more than two courses of SCS per year because of the cumulative side-effects.

Risk of SCS use22-24

  • High blood pressure
  • Hyperglycemia
  • Weight gain
  • Osteoporosis
  • Cataracts
  • Glaucoma
  • Sleep disturbances
icon

EPOS GUIDELINES CONSIDER A REDUCED NEED FOR SCS AS A CRITERION OF BIOLOGIC RESPONSE22

NP Score

THE ONLY APPROVED BIOLOGIC TO REPORT A >2-POINT NPS IMPROVEMENT IN PHASE 3 TRIALS1,25,26

DUPIXENT significantly reduced the size of nasal polyps vs placebo as measured by bilateral endoscopic NPS as early as Week 4, sustained through Week 521,25,26

Endoscopy

icon

37% improvement at Week 521,13

-1.71 improvement at Week 24 (co-primary endpoint) from a baseline score of 6.18 with DUPIXENT 300 mg Q2W + INCS (n=295, pooled DUPIXENT arms) vs 0.10 worsening from a baseline score of 5.96 with placebo + INCS (n=153) (LSM difference: -1.80 [95% CI: -2.10, -1.51])1

-2.24 improvement at week 52 from a baseline score of 6.07 (secondary endpoint) with DUPIXENT 300 mg Q2W + INCS (n=150) vs 3% worsening with placebo + INCS (n=153) (0.15 from a baseline score of 5.96) (LSM difference: -2.40 [95% CI: -2.77, -2.02])1

NASAL POLYPS ARE A MANIFESTATION OF CRS—TYPE 2 INFLAMMATION IS AN UNDERLYING CAUSE11

Bilateral endoscopic NPS can help measure polyp formation and recurrence, which are key signs of Type 2 inflammation11,27,28

NPS improvement >2 indicates substantial relief of obstruction27,28

NPS improvement

icon

TARGET TYPE 2 INFLAMMATION TO REDUCE NASAL POLYP SIZE AND LIMIT RECURRENCE11,27,28

LMK-CT

TARGET UNDERLYING TYPE 2 INFLAMMATION TO SEE SUSTAINED DECREASES IN SINUS OPACIFICATION1

DUPIXENT significantly decreased LMK-CT scan score vs placebo at Week 24, with greater improvement seen at Week 521

Baseline vs Week 52

Endoscopy

icon

THE ONLY BIOLOGIC TO REPORT LMK-CT RESULTS IN THE APPROVED LABEL1,25,26

5.21 improvement at Week 24 from a baseline score of 18.12 (secondary endpoint) with DUPIXENT 300 mg Q2W + INCS (n=295, pooled DUPIXENT arms) vs 0.09 improvement (from a baseline score of 17.65) with placebo + INCS (n=153) (LSM difference: -5.13 [95% CI: -5.80, -4.46])1

6.83 improvement at Week 52 from a baseline score of 18.42 (secondary endpoint) with DUPIXENT 300 mg Q2W + INCS (n=150) vs 0.11 worsening from a baseline score of 17.65 with placebo + INCS (n=153)(LSM difference: -6.94 [95% CI: -7.87, -6.01])1

Secondary Efficacy

Quality of Life

PATIENTS REPORTED IMPROVED SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE1,13

DUPIXENT significantly decreased SNOT-22 score vs placebo as early as Week 4, sustained through Weeks 24 and 521,13

Change in SNOT-22 score through Week 52 in SINUS-5213

chart

icon

DUPIXENT IMPROVED A COMPOSITE SCORE, INCLUDING PHYSICAL SYMPTOMS, SLEEP AND FATIGUE ISSUES, AND PSYCHOSOCIAL LIMITATIONS1,13

The SNOT-22 questionnaire is a patient-reported assessment of 22 symptoms and consequences of CRS with nasal polyps, including29:

  • Nasal obstruction
  • Nasal discharge
  • Ear fullness/pain
  • Sneezing
  • Cough
  • Loss of smell/taste
  • Difficulty falling asleep
  • Waking up at night
  • Fatigue
  • Reduced productivity and concentration
  • Frustration, restlessness, and irritability
  • Sadness and embarrassment

Coexisting Asthma

In patients who have CRS with nasal polyps and coexisting asthma,
DUPIXENT IMPROVED BREATHING AND QUALITY OF LIFE13

DUPIXENT significantly improved lung function and asthma control (ACQ-6) while simultaneously improving CRS with nasal polyps outcomes13

Change in lung function through Week 24 in SINUS-5213

chart

Pre-bronchodilator FEV1

170 mL improvement at Week 24 from baseline in pre-bronchodilator FEV1 with DUPIXENT 300 mg Q2W + INCS (n=176, pooled DUPIXENT arms) vs -50 mL worsening with placebo (LSM difference vs placebo: 210 mL [95% CI: 110, 320 mL])13

ACQ-6

-0.78 improvement at Week 24 from a baseline ACQ-6 score of 1.55 with DUPIXENT 300 mg Q2W + INCS (n=176, pooled DUPIXENT arms) vs 0.08 worsening from a baseline score of 1.63 with placebo (LSM difference -0.87 [95% CI: -1.07, -0.66])13

DUPIXENT WAS STUDIED IN THE LARGEST CLINICAL TRIAL PROGRAM IN CRS WITH NASAL POLYPS1,a

Patients were enrolled regardless of prior surgery or systemic steroid use1

 

SINUS-24 (N=276) 24 Weeks

SINUS-52 (N=448) 52 Weeks

Randomized, phase 3 trial

DUPIXENT + INCS 300 mg Q2W for 24 weeks (n=143)

Placebo + INCS for 24 weeks (n=133)

DUPIXENT + INCS 300 mg Q2W for 52 weeks (n=150)b

DUPIXENT + INCS 300 mg Q2W for 24 weeks, followed by Q4W through Week 52 (n=145)c

Placebo + INCS for 52 weeks (n=153)

Study population

>Adults (≥18 years) on background INCS with CRSwNP despite prior sino-nasal surgery or prior treatment with, or who were ineligible to receive or were intolerant to, systemic steroids in the past 2 yearsd

>Patients with chronic rhinosinusitis without nasal polyps were not included in these trials

>Rescue with systemic steroids or surgery was allowed at investigators’ discretion

>The total population of patients in SINUS-24 and SINUS-52 was unrestricted by minimum baseline blood eosinophil count

80Percent_Callout

SINUS-24 Selected Baseline Demographics: Male: 57%; mean CRSwNP duration (SD): 11 (9) years; patients with >1 prior surgery: 72%; patients with systemic steroid use in previous 2 years: 65%; mean bilateral endoscopic NPS (SD), range 0-8: 5.8 (1.3); mean LMK sinus CT total score (SD), range 0-24: 19.0 (4.4); mean UPSIT score (SD), range 0-40: 14.6 (8.5); mean loss of smell score (AM) (SD), range 0-3: 2.7 (0.5); mean SNOT-22 total score (SD), range 0-110: 49.4 (20.2).1

SINUS-52 Selected Baseline Demographics: Male: 62%; mean CRSwNP duration (SD): 11 (10) years; patients with >1 prior surgery: 58%; patients with systemic steroid use in previous 2 years: 80%; mean bilateral endoscopic NPS (SD), range 0-8: 6.1 (1.2); mean LMK sinus CT total score (SD), range 0-24: 18.0 (3.8); mean UPSIT score (SD), range 0-40: 13.6 (8.0); mean loss of smell score (AM) (SD), range 0-3: 2.8 (0.5); mean SNOT-22 total score (SD), range 0-110: 51.9 (20.9).1

Patient Profiles

IDENTIFY TYPE 2 INFLAMMATION IN PATIENT TYPES LIMITED BY CRS WITH NASAL POLYPS SYMPTOMS2,9

Look for signs of type 2 inflammation and increased disease severity to break the cycle with biologic therapy2,9,30

Signs of type 2 inflammation include:2,9

  • Coexisting type 2 inflammatory conditions, such as:
    • AERD
    • Allergic rhinitis
    • Asthma
    • NSAID hypersensitivity
  • Impairment to sense of smell
  • Polyp or symptom recurrence

Safety

ESTABLISHED SAFETY PROFILE WAS CONSISTENT THROUGH WEEK 521

DUPIXENT is a fully human monoclonal antibody with a safety profile comparable to placebo1,a

Adverse events in CRSwNP, asthma, and atopic dermatitis clinical trials1,a

MedDRA System Organ Class

Frequencyb

Adverse reaction

Blood and lymphatic system disorder

Common

Eosinophilia

General disorders and administration site conditions

Common

Injection site reactions (includes erythema, edema, pruritus, pain, swelling, and bruising)d

Musculoskeletal and connective tissue disorders

Common

Arthralgiac

Immune system disorders

Uncommon

Rare

Angioedemac

Anaphylactic reaction Serum sickness reaction Serum sickness-like reaction

Skin and subcutaneous tissue disorders

Uncommon

Facial rashc

Adverse events occurring predominantly in atopic dermatitis clinical trials

Eye disorders

Common

Conjunctivitis allergic

Eye disorders

Uncommon

Blepharitisd
Dry eyed
Eye pruritusd
Keratitisc

Eye disorders

Rare

Ulcerative keratitisc,d

Infections and infestations

Common

Conjunctivitis
Oral herpes

In the safety pool, the proportion of patients who discontinued treatment due to adverse events:1

2.0% of the DUPIXENT group

4.6% of the placebo group

icon

DUPIXENT IS NOT AN IMMUNOSUPPRESSANT1

Legacy

7-YEAR OF LEGACY ACROSS INDICATIONS DRIVEN BY TYPE 2 INFLAMMATION1,a

Approved across 6 indications driven by type 2 inflammation1

icon

Atopic dermatitis
uncontrolled severeb

icon

Asthma
severe type 2 asthma or OCS-dependentc

icon

CRS with nasal polyps
severe inadequately controlled

icon

Prurigo nodularis
uncontrolled moderate to severe

icon

Eosinophilic esophagitis
inadequately controlled

icon

COPD
uncontrolled while on optimized inhaled therapyd

ATOPIC DERMATITIS

DUPIXENT is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

DUPIXENT is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy.

ASTHMA

DUPIXENT is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.

DUPIXENT is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.

CRS WITH NASAL POLYPS (CRSwNP)

DUPIXENT is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.

PRURIGO NODULARIS (PN)

DUPIXENT is indicated for the treatment of adults with moderate-to-severe PN who are candidates for systemic therapy.

EOSINOPHILIC ESOPHAGITIS (EoE)

DUPIXENT is indicated for the treatment of eosinophilic esophagitis in adults and children 1 year or older, weighing at least 15 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Dupixent is indicated in adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils on a combination of an inhaled corticosteroid (ICS), a long-acting beta2- agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.

For additional information, click here for the SmPC.

Dosing

DUPIXENT OFFERS THE CHOICE OF AT-HOME OR IN-OFFICE ADMINISTRATION1

Recommended dosing for patients with uncontrolled CRS with nasal polyps1

18+ YEARS

300 mga

every-other-week

NO LOADING DOSE

Designed with patients in mind. DUPIXENT has 2 self-administration options1

Pre-filled Syringe

Pre-filled Pen

  • Subcutaneous injection
  • Needle shield
  • Finger grip for comfort
  • Visual feedback
  • Portable
  • Autoinjector
  • Hidden needle
  • 2-step safety control feature
  • Visual and audible feedback
  • Portable

Dosing_PreFilledSyringes

Dosing_PreFilledPens

DUPIXENT is intended for use under the guidance of a healthcare provider. A patient may self-inject DUPIXENT after training in subcutaneous injection technique using the pre-filled syringe or the pre-filled pen. Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use according to the Instructions for Use.1

DUPIXENT can be administered in the office under the guidance of a healthcare provider if the patient is not an appropriate candidate for self-administration.1

SmPC

References